Alnylam Pharmaceuticals

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiranā–¼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35%...
675 West Kendall St Cambridge, MA 02142 USA

617.551.8200